ES2523459T3 - Derivados de benzisoxazol - Google Patents

Derivados de benzisoxazol Download PDF

Info

Publication number
ES2523459T3
ES2523459T3 ES06710393.7T ES06710393T ES2523459T3 ES 2523459 T3 ES2523459 T3 ES 2523459T3 ES 06710393 T ES06710393 T ES 06710393T ES 2523459 T3 ES2523459 T3 ES 2523459T3
Authority
ES
Spain
Prior art keywords
methyl
benzisoxazol
piperidin
metil
del
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES06710393.7T
Other languages
English (en)
Spanish (es)
Inventor
Hirohide Noguchi
Isao Sakurada
Chikara Uchida
Nobuaki Waizumi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Raqualia Pharma Inc
Original Assignee
Raqualia Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Raqualia Pharma Inc filed Critical Raqualia Pharma Inc
Application granted granted Critical
Publication of ES2523459T3 publication Critical patent/ES2523459T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES06710393.7T 2005-02-25 2006-02-15 Derivados de benzisoxazol Expired - Lifetime ES2523459T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US65665305P 2005-02-25 2005-02-25
US656653P 2005-02-25
US71597705P 2005-09-09 2005-09-09
US715977P 2005-09-09
PCT/IB2006/000313 WO2006090224A1 (en) 2005-02-25 2006-02-15 Benzisoxazole derivatives

Publications (1)

Publication Number Publication Date
ES2523459T3 true ES2523459T3 (es) 2014-11-26

Family

ID=36101715

Family Applications (1)

Application Number Title Priority Date Filing Date
ES06710393.7T Expired - Lifetime ES2523459T3 (es) 2005-02-25 2006-02-15 Derivados de benzisoxazol

Country Status (7)

Country Link
US (1) US8816090B2 (https=)
EP (1) EP1856114B1 (https=)
JP (2) JP4970290B2 (https=)
CA (1) CA2598516C (https=)
DK (1) DK1856114T3 (https=)
ES (1) ES2523459T3 (https=)
WO (1) WO2006090224A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0525068D0 (en) 2005-12-08 2006-01-18 Novartis Ag Organic compounds
JP5540099B2 (ja) 2009-09-14 2014-07-02 スベン ライフ サイエンシズ リミティド ５−ｈｔ４受容体リガンドとしての１，２−ジヒドロ−２−オキソキノリン化合物
CA2788656A1 (en) * 2010-02-16 2011-08-25 Pfizer Inc. (r)-4-((4-((4-(tetrahydrofuran-3-yloxy)benzo[d]isoxazol-3-yloxy)methyl)piperidin-1-yl)methyl)tetrahydro-2h-pyran-4-ol, a partial agonist of 5-ht4 receptors
BR112013020641B1 (pt) 2011-02-25 2021-11-03 Yuhan Corporation Composto, composição farmacêutica, processos para a preparação de composto e respectivo uso ou de seu sal farmaceuticamente aceitável
JP6051431B2 (ja) * 2011-03-23 2016-12-27 ラクオリア創薬株式会社 消化管運動促進剤として機能する５−ｈｔ４受容体作動物質
WO2012157288A1 (en) 2011-05-18 2012-11-22 Raqualia Pharma Inc. Polymorph form of 4-{[4-({[4-(2,2,2-trifluoroethoxy)-1,2-benzisoxazol-3-yl]oxy}methyl)piperidin-1-yl]methyl}-tetrahydro-2h-pyran-4-carboxylic acid
PT2758394E (pt) 2011-09-19 2015-04-22 Suven Life Sciences Ltd Compostos heteroarilo como ligandos de recetores 5-ht4
BR112015011392A2 (pt) * 2012-11-21 2017-07-11 Raqualia Pharma Inc formas polimórficas de ácidos, processo de preparação, composição farmacêutica e uso das mesmas
CN105164119B (zh) 2013-03-20 2017-12-08 苏文生命科学有限公司 作为5‑ht4受体激动剂的5‑氨基‑喹啉‑8‑甲酰胺衍生物
MX368017B (es) 2013-12-16 2019-09-13 Suven Life Sciences Ltd Compuestos de indazol como agonistas del receptor de 5-ht4.
US9833447B2 (en) * 2014-05-16 2017-12-05 Raqualia Pharma Inc. 5-HT4 receptor agonist for gastroparesis
CA2944982C (en) * 2014-05-20 2022-06-07 Raqualia Pharma Inc. Benzisoxazole derivative salt
SG11201706501VA (en) 2015-02-13 2017-09-28 Suven Life Sciences Ltd AMIDE COMPOUNDS AS 5-HT<sb>4</sb> RECEPTOR AGONISTS
WO2026003716A1 (en) 2024-06-27 2026-01-02 Pfizer Inc. Process for preparing n-(6-((1h-pyrazol-1-yl)methyl)-4-methoxybenzo[d]isoxazol- 3-yl)-2-methoxybenzenesulfonamide

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4352811A (en) * 1981-11-12 1982-10-05 Hoechst-Roussel Pharmaceuticals Inc. 3-(1-Substituted-4-piperidyl)-1,2-benzisoxazoles
FR2654104B1 (fr) * 1989-11-07 1992-01-03 Adir Nouveaux derives du 1,2-benzisoxazole, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent.
FR2674855B1 (fr) * 1991-04-03 1994-01-14 Synthelabo Derives de piperidine, leur preparation et leur application en therapeutique.
EP0602242A4 (en) * 1991-08-22 1994-06-29 Yoshitomi Pharmaceutical Benzisoxazole compound and use thereof.
JPH05320160A (ja) * 1991-08-22 1993-12-03 Yoshitomi Pharmaceut Ind Ltd ベンゾイソオキサゾール化合物
JPH0641125A (ja) * 1992-03-26 1994-02-15 Yoshitomi Pharmaceut Ind Ltd ベンゾイソオキサゾール化合物およびその用途
EP0873990A1 (en) * 1995-09-22 1998-10-28 Yoshitomi Pharmaceutical Industries, Ltd. Benzoic acid compounds and medicinal use thereof
FR2749304B1 (fr) * 1996-06-04 1998-06-26 Adir Nouveaux derives du 3-(piperid-4-yl)1,2-benzisoxazole et du 3-(piperazin-4-yl)1,2-benzisoxazole, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent
JP4627882B2 (ja) * 1998-02-09 2011-02-09 デユフアー・インターナシヨナル・リサーチ・ベー・ブイ Ｄ４−アンタゴニスト活性を有するベンズイソキサゾール誘導体

Also Published As

Publication number Publication date
EP1856114B1 (en) 2014-08-20
US8816090B2 (en) 2014-08-26
WO2006090224A1 (en) 2006-08-31
JP2008531539A (ja) 2008-08-14
JP4970290B2 (ja) 2012-07-04
DK1856114T3 (en) 2014-11-17
JP5509236B2 (ja) 2014-06-04
EP1856114A1 (en) 2007-11-21
JP2012144547A (ja) 2012-08-02
CA2598516A1 (en) 2006-08-31
US20080207690A1 (en) 2008-08-28
CA2598516C (en) 2010-05-11

Similar Documents

Publication Publication Date Title
JP5509236B2 (ja) ベンズイソキサゾール誘導体
US7776885B2 (en) Benzimidazolone compounds having 5-HT4 receptor agonistic activity
US20080108660A1 (en) Benzimidazolone Carboxylic Acid Derivatives
US7589109B2 (en) Oxyindole derivatives
JP5075818B2 (ja) ５ｈｔ４受容体アゴニストとしてのインダゾールカルボキサミド誘導体
US7737163B2 (en) Benzimidazolone carboxylic acid derivatives
JP4129445B2 (ja) ベンズイミダゾロンカルボン酸誘導体
JP2008509088A (ja) ベンズイミダゾロンカルボン酸誘導体
HK1104031B (zh) 苯并咪唑酮羧酸衍生物